<DOC>
	<DOCNO>NCT01546532</DOCNO>
	<brief_summary>This study assess renal hemodynamic effect RLX030 infusion subject chronic heart failure . In addition safety effect renal function biomarkers assess .</brief_summary>
	<brief_title>Renal Hemodynamic Effects RLX030A Subjects With Chronic Heart Failure ( CHF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Male female heart failure patient body weight &lt; 160 kg , standard therapy include stable dose furosemide 40240 mg/day orally ( p.o ) . equivalent dose loop diuretic , reduce systolic function ( LVEF ≤ 45 % measure within past 6 month ) , BNP ≥ 100 pg/mL NTproBNP ≥ 400 pg/mLNYHA Class II III , worsen symptom , e.g . fatigue , dyspnea , breathlessness within 3 month Mild moderate renal impairment Exclusion criterion : Systolic blood pressure ( SBP ) &lt; 110 mm Hg time randomization Administration intravenous radiographic contrast agent within 72 hour prior randomization acute contrastinduced nephropathy time randomization Current use nonsteroidal antiinflammatory drug ( NSAIDs ) Current plan ( completion study drug infusion ) treatment i.v . therapy , include vasodilator ( include nesiritide ) , positive inotropic agent , vasopressor , levosimendan , mechanical support ( intraaortic balloon pump , endotracheal intubation , mechanical ventilation , ventricular assist device ) . Clinically significant hepatic impairment define hepatic encephalopathy degree total bilirubin &gt; 50 μmol/l ( 3 mg/dl ) , patient warfarin therapy , INR &gt; 2.0 ( Prothrombin Time &gt; 2 * ULN ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>RLX030</keyword>
	<keyword>hemodynamics</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>